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ABSTRACT 
Introduction: Transcriptomes in saliva can be used as potential biomarkers for both diagnostic 
and response to treatment in oral squamous cell carcinoma (OSCC). In this review, we 
explored their application in this increasingly common disease 
Materials and methods: PubMed, EMBASE, Scopus, Web of Science and grey literature from 
January 1990 to May 2017 were searched. Two independent reviewers performed the study 
selection according to eligibility criteria. 
Results: A total of nine studies were included. Three studies showed increased expression of 
DUSP1, IL8, IL1B, OAZ1, SAT1, S100P and two showed increased expression of miRNA-
31 amongst study groups compared to normal healthy controls. The sensitivity ranged from 
14% - 100%, while the specificity ranged from 38% - 100%. miRNA-27b had the highest 
AUC (write in full) of 0.9643 and DUSP1 had the minimum AUC of 0.41. 
Conclusion: Salivary transcriptomics may play an effective role as a robust and non-invasive 
biomarker sighting tool for the diagnosis and management of OSCC. 
 
Key words: Biomarker; Oral squamous cell carcinoma; RNA; Saliva; Transcriptomics, 
Systematic review  
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INTRODUCTION 
Oral squamous cell carcinoma (OSCC) is the sixth most common cancer with a global 
incidence of approximately 275,000 new cases.1,2 Developing countries in South East Asia 
have the highest incidence of OSCC, with oral cancer being the most common cancer among 
men and accounting for nearly 25% of all new cases annually.3 In addition, many countries in 
the European Union and parts of the United States have reported a rising incidence in oral 
and oropharyngeal cancer and mortality rates in young adults.4-6 In addition, the five-year 
survival rate of cancers of the oral cavity and oropharynx is approximately 50%.2,7 In an 
attempt to reduce the high mortality and morbidity rates of oral cancer, it is critical to develop 
tools that can accurately identify and distinguish OSCC in its early stages.    
Saliva may provide pertinent information regarding the disease status of oral mucosa due to 
its direct contact with oral lesions. An increasing number of studies are utilizing saliva as a 
potentially diagnostic tool for diseases including oral cancers,8 pancreatic cancer,9 6M|JUHQ¶V
syndrome,10 HIV ,11,12 Hepatitis A, B, and C,13-15 diabetes mellitus,16 Alzheimer disease.17 
Saliva contains high levels of miRNAs that are non-coding single-stranded RNAs comprised 
of approximately 20 nucleotides, that can be used as potential biomarkers for the diagnosis of 
OSCC as well as evaluating response to different treatment modalities and predicting disease 
prognosis.18   
In recent years, transcriptomics has emerged as a robust and cost-effective biomarker sighting 
tool capable of simultaneously quantifying a large set of transcriptomes in a miniaturized, 
automated format. A transcriptome is defined as mRNA in a cell which is the template for 
protein synthesis through translation and gene expression. Transcriptomics have proven 
benefit in oncology, mainly due to the relative ease of collecting samples.19,20 In addition, the 
technique has also shown promise in identifying genetic fingerprints that are predictive of 
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disease outcome using gene expression profiling .20 The aim of this study was to 
systematically quantify the existing literature and assess the role of salivary transcriptomics 
in the diagnostic and prognostic prediction of OSCC. 
 
MATERIAL AND METHODS 
Protocol and registration 
International Prospective Register of Systematic Reviews (PROSPERO) database was 
searched for any registered protocols on similar topic. In addition, the current systematic 
review was registered as a protocol in the PROSPERO platform (ID: 121630). The systematic 
review was reported according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement .21 
 
Eligibility Criteria 
Inclusion criteria 
The PECOS framework (Population, Exposure, Comparison, Outcomes, Studies) was used to 
formulate the focused question of the review, of which: P) Patients with diagnosis of OSCC; 
I) Transcriptomics analysis; C) Patients with no history of HNC; O) Diagnostic and 
prognostic prediction of OSCC; S) Observational studies and/or Clinical trials.  
Observational studies (case-control, cross-sectional or population-based) and/or clinical trials 
(randomized controlled trial) that recruited patients with clinically and/or histologically 
confirmed diagnosis of OSCC and evaluated the diagnostic and prognostic prediction by 
utilizing analytics technology of transcriptomics were included. Only articles published in 
English language were included. 
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Exclusion criteria 
The following exclusion criteria were applied: (1) Studies that did not evaluate the analytics 
technology of transcriptomics; (2) case-reports, reviews, experimental studies, short 
communications and personal opinions, letters to the editor, and conference abstracts. 
 
Focused question 
The focus question was: ³Does salivary transcriptomics play a role in diagnostic and 
prognostic prediction of oral cancer"´ 
 
Search strategy 
Detailed automated literature searches were performed in PubMed, EMBASE, Scopus, and 
Web of Science from January 1990 up to and including May 2017. An additional search of 
the grey literature was carried out on Google Scholar, ProQuest, and OpenGrey. Reference 
lists of all included articles were manually searched to identify any potentially relevant 
articles. EndNote software (EndNote X7®, Thomson Reuters, Philadelphia, USA) was used to 
manage the references and remove any duplicate articles.  
 
Various combinations of descriptors extracted from Medical Subject Headings (MeSH) and 
free terms were used; ³RPLFV´ $1' ³RUDO FDQFHU´ RU ³RPLFV´ $1' ³RUDO VXEPXFRXV
ILEURVLV´ RU ³RPLFV´ $1' ³RUDO OHXNRSODNLD´ RU ³RPLFV´ $1' ³RUDO HU\WKURSODNLD´ RU
³RPLFV´$1'³RUDOOLFKHQSODQXV´RU³RPLFV´$1'³RUDOVTXDPRXVFHOOFDUFLQRPD´ 
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Study selection and data extraction 
The study selection process was completed in two stages. First, titles and abstracts of all 
identified articles were screened by two independent reviewers (KHA and SP) using a 
standardized guide. This was followed by retrieval of full texts of studies that met the 
eligibility criteria and reviewed independently by the same two reviewers using a 
standardized and pilot tested form. Any disagreements on study selection were mutually 
discussed and a consensus was made before inclusion of the study. 
Two reviewers (KHA and SP) independently collected the data on study characteristics 
(author, year of study and country), study design, sample population, OSCC sub-site, 
methods used for transcriptomics analysis, statistical findings, and conclusions. 
 
Risk of bias assessment 
The risk of bias of included studies was assessed using the Newcastle Ottawa scale (NOS).22  
Two reviewers (KHA and SP) independently evaluated the quality of studies based on the 
following parameters: Selection, Comparability, and Outcome/Exposure. A maximum of 4 
stars in selection domain, 2 stars in comparability domain and 4 stars in outcome/exposure 
GRPDLQ ZHUH JLYHQ 7KH LQFOXGHG VWXGLHV ZHUH TXDOLILHG DV ³*RRG´ ³)DLU´ DQG ³3RRU´
TXDOLW\EDVHGRQWKHWRWDO126VFRUHWKH\DFKLHYHG6WXGLHVZLWKD126VFRUHDQGZHUH
considered good-quality studies. 
Statistical analysis 
&RKHQ¶VNDSSDVWDWLVWLFwas used to calculate the agreement between the two reviewers (KHA 
and SP). Descriptive statistics for all included studies were populated and reviewed. NOS 
scores based on the assessment of quality of each study were also reported.  
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RESULTS 
Study selection 
Of 23 full texts assessed, 14 articles were excluded, giving, nine included articles that met the 
eligibility criteria (Fig. 1).  The inter-examiner agreement (Kappa) was 0.98 in the first stage 
(title and abstract screening stage) and 1.00 in the second stage (full-text reading stage). 
Studies characteristics 
Of the 9 included studies,23-31 five were from United States,23-25, 27, 28 two from Taiwan,26, 30 
and one each from Saudi Arabia,29 and Turkey31. All included studies had a case-controlled 
design and all utilized quantitative polymerase chain reaction (qPCR) to quantify salivary 
miRNA; three studies also utilized ELISA,25 In-situ hybridization 30 and micro-array based 
miRNA analysis. 31 Five studies reported sites of the oral cancer among the study group,25, 26, 
29-31
 while the remaining studies did not report. The studies were carried out among 
Caucasian, Asian, African, Taiwanese, and Arabic populations. Table 1 provides the detailed 
characteristics of the included studies. 
Risk of bias assessment 
The NOS score for the quality of the included studies ranged from 5 to 7 (Figure 2). Only 
three studies 23, 26, 27, 31 KDGUHTXLUHG126VFRUHRIµ¶WREHFRQVLGHUHGJRRG-quality studies, 
while three studies24, 28-30 VFRUHG µ¶ DQG RQO\ RQH VWXG\25 had D 126 VFRUH RI µ¶ 7KH
majority of studies scored high in the selection domain and outcome/exposure domain. 
Studies also scored high in the comparability domain with the exception of one study25 that 
VFRUHGµ¶ 
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Analyzed salivary transcriptomes 
All nine included studies provided significant data for the analyzed salivary transcriptomes. 
Three studies showed increased expression of DUSP1, IL8, IL1B, OAZ1, SAT1 and S100P 
in OSCC patients compared to healthy controls. 23, 25, 27 Two studies showed that expression 
of miRNA-31 was upregulated among OSCC and oral pre-malignant disease (OPMD) 
patients compared to healthy controls.26,30 One study reported 11 miRNAs were 
downregulated (miRNA-136, miRNA-147, miRNA-1250, miRNA-148a, miRNA-632, 
miRNA-646, miRNA668, miRNA-877, miRNA-503, miRNA-220a, miRNA-323-5p), and 2 
miRNAs were upregulated (miRNA-24, miRNA-27b) in OSCC patients.28 
Sensitivity, specificity and receiver operator characteristic (ROC) curve analysis 
Majority of the studies reported sensitivity, specificity and AUC (Area under ROC curve) 
analysis for the salivary transcriptomes (Table 2). The sensitivity ranged from 14% - 100%, 
while the specificity ranged from 38% - 100%. OAZ1, miRNA-21 and miRNA-31 were 
reported to have the highest sensitivities, and miRNA-31 and miRNA-27b had the highest 
specificities. DUSP1 was reported to have the lowest sensitivity of 14% and OAZ1 had the 
lowest specificity of 38%. AUC reported was in the range of 0.41 ± 0.9643; miRNA-27b had 
the highest AUC of 0.9643 and DUSP1 had the minimum AUC of 0.41.  
DISCUSSION 
Transcriptomics is a cost-efficient technology that can help in the quantification of many 
defined mRNA species in a miniaturized automated manner.32 Identifying altered 
transcriptomes along with RNA sequencing can facilitate in classification and progression of 
diseases.  
While assessing quality of the included studies using NOS score, only four studies were 
classified as good-quality.23,25,26,31. These reported OSCC patients that were confirmed either 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
through histological analysis or hospital records and adjusted their risk estimates for other 
confounding factors, including smoking. In addition, controls were age, sex, smoking and 
alcohol history matched, and had the same method of exposure assessment as the cases. In 
contrast, studies that scored low on NOS did not provide adjustment for other confounding 
factors and did not report any histological and/or hospital records. 
A wide range of salivary transcriptomes were analyzed in the included studies. mRNA 
transcripts of IL8, IL1B, DUSP1, H3F3A, OAZ1, S100P, and SAT were evaluated using the 
saliva samples of OSCC patients and healthy controls.23 All of these potential salivary RNA 
biomarkers had higher sensitivity and specificity in identifying and differentiating OSCC. In 
a similar study, Brinkmann et al.25 (2011)  evaluated salivary transcriptomes IL8, IL1B, 
DUSP1, OAZ1, S100P, SAT1 and reported significant expression IL8, IL1B, S100P, SAT1 
in OSCC patients when  compared to healthy controls.25 Another found significantly elevated 
levels of all these salivary transcriptomes amongst OSCC patients; expression of IL-8 and 
SAT was increased in all 5 cohorts, expression of IL1B, DUSP1, OAZ1 and H3F3A was 
increased in only 3 cohorts, Expression of S100P was increased in 2 cohorts.27 
Park et al24 (2009)  found two salivary miRNAs, miR-200a and miR-125a, that were present 
in significantly lower levels in OSCC patient than in healthy controls (24). Studies have 
reported differential expression of miR-200a in head and neck and other cancer cell lines.33-36 
In addition, miR-125a along with its homolog miR-125b have been associated with reduced 
ERBB2 and ERBB3 oncogenic protein levels in a human breast cancer cell line SKBR3.37 
Although this study reported reduced levels of miR-200a in OSCC patients, higher levels of 
miR-200a have been presented in various oral squamous cell lines.33-36 These contrasting 
results may be due to the difference in examining cell free state of miRNAs when compared 
to those in living cells. The supernatant saliva used for salivary transcriptomic analysis in the 
study is cell free phase of saliva, hence, the supernatant saliva contained some miRNA that 
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were byproducts of cell death. Similar to regulatory mRNAs, cancer-specific miRNAs may 
also have a more rapid degradation and/or a shorter half-life during cell death.38 
Two studies evaluated the role of miR-31 as a biomarker for early detection and prognostic 
indicator of OPMD and OSCC.26, 30 Both reported increased expression levels of miR-31 in 
OPMD and OSCC patients when compared to healthy controls. Although there is 
accumulated evidence that show a strong association of miR-31 in the pathogenesis of 
various cancers including oral cancer, other studies that utilized salivary microarray analysis 
did not have similar findings, 28, 39 perhaps due to discrepancies in the predisposing factors of 
the OPMD patients and/or histological features and lesion location. Mucosal lesions with 
distinct histological features may demonstrate varied expression of miRNAs. In addition, 
predisposing factors such as tobacco have shown to affect the expression of miR-31 in lung 
cancer specimens compared to adjacent normal lung tissues.40 An experimental study on mice 
treated with 4NQO as carcinogen also showed increased expression of salivary miR-31.41 
There are a few limitations to this review. Firstly, there was a lack of population variation in 
majority of the included studies. The studies were carried out mostly among Caucasian, 
Asian, African, Taiwanese, and Arabic populations. There is a need for exclusive studies in 
other ethnic population such as Indian population, especially keeping in mind the fact that 
these regions have some of the highest prevalence rates for oral cancer. Furthermore, the 
included studies were case-control biomarker development studies and did not follow the 
essential aspects of eliminating bias for biomarker research such as biomarker performance 
criteria, the biomarker test, study size and vigorous follow-up.  
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CONCLUSION 
Salivary transcriptomes may be potentially useful biomarkers in the diagnostic and 
prognostic prediction of OSCC. However, further well-designed large-scale studies with 
detailed investigations and vigorous follow-up are needed to validate the sensitivity and 
specificity of these biomarkers before their more widespread use can be recommended.  
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Fig. 1. Flow diagram of literature search and selection criteria. 
Figure 2. Assessment of the quality of studies included using Newcastle-Ottawa (NOS) scale 
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Table 1. Characteristics of the included studies  
Table 2. Sensitivity, specificity and receiver operator characteristic (ROC) curve analysis of 
OSCC-associated salivary biomarkers 
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Author et al. 
(year), 
Country 
Study design Sample population Oral cancer site Platform  Molecules 
analyzed Outcome Conclusion 
Li et al. 
(2004), USA23 
x Case-control 
x Medical 
Centers at University of 
California, Los Angeles 
(UCLA) and University 
of Southern California 
(USC), Los Angeles, 
CA; and University of 
California San Francisco, 
San Francisco, CA 
x Cases: 32 OSCC 
patients; Mean age 49.8±7.6 
y 
x Controls: 32 
healthy individuals; age-sex-
and smoking history 
matched; Mean age 49.1±5.9 
y 
 
x NS x qPCR x IL8 
x IL1B 
x DUSP1 
x H3F3A 
x OAZ1 
x S100P 
x SAT 
x Expression of  
DUSP1, H3F3A, IL1B, 
IL8, OAZ1, S100P, and 
SAT was increased in 
the saliva of OSCC 
patients compared to 
controls 
x Salivary 
transcriptomics is a 
useful tool for oral 
cancer detection 
Park et al. 
(2009), USA24 
x Case-control 
x UCLA School 
of Dentistry Dental 
Research Institute, Los 
Angeles, CA 
x Cases: 50 OSCC 
patients; Average age 56 y; 
32M, 18F 
x Controls: 50 
healthy individuals; age-
gender-ethnicity and 
smoking history matched; 
Average age 52 y; 29M, 21F 
x NS x RT-
preamp-qPCR 
x miR-
142-3p 
x miR-
200a 
x miR-
125a 
x miR-93 
x miR-125a and 
miR-200a were present 
in significantly lower 
levels (p<0.05) in the 
saliva of OSCC patients 
than in control samples 
x Saliva 
miRNAs can be 
used for oral cancer 
detection 
Brinkmann et 
al. (2011), 
USA25 
x Case-control 
x Clinical Center 
of Serbia and 
Stomatology Faculty 
University of Belgrade, 
Belgrade, Serbia 
x Cases: 35 OSCC 
patients; Mean age 
60.94±12.30 y; 30M, 5F 
x Controls: 51 
healthy individuals; Mean 
age 38.24±12.50 y; 28M, 
23F 
x Buccal 
mucosa 
x Gingiva 
x Others 
x qPCR  
x ELISA 
x DUSP1 
x IL8 
x IL1B 
x OAZ1 
x SAT1 
x S100P 
x Expression of 
IL8, IL1B, SAT1, 
S100P was increased in 
OSCC patients 
compared to controls 
x Salivary 
transcriptomic 
biomarkers are 
discriminatory & 
reproducible in 
OSCC 
Liu et al. 
(2012), 
Taiwan26 
x Case-control 
x Department of 
Stomatology, Taipei 
Veterans General 
Hospital, Taipei, Taiwan 
x Cases: 45 OSCC 
patients; 53.7±1.4 y; 43M, 
2F 
x Cases: 10 OVL 
patients; 49.5±2.5 y; 9M, 1F 
x Controls: 24 
healthy individuals; age, sex, 
and oral habits matched; 
Mean age 51.1±1.7 y; 23M, 
1F   
x Buccal 
mucosa 
x Gingiva 
x Tongue 
x Others 
x qRT-
PCR 
x miR-31 x Expression of 
salivary miR-31 was 
increased in OSCC 
patients  
x Expression of 
salivary miR-31 was 
not increased in OVL 
patients compared to 
controls 
x Salivary 
miR-31 can be a 
potential biomarker 
for early detection 
and postoperative 
follow-up of OSCC 
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Elashoff et al. 
(2012), USA27 
x Case-control 
x Medical 
Centers at the University 
of California, Los 
Angeles (UCLA) and 
University of Southern 
California (USC) and 
Veteran Hospital in 
greater Los Angeles 
(VAGLA); 2004 to 2007 
x Cohort 1: Cases - 
48 OSCC patients; Mean age 
62.7±12.1 y; 34M, 16F. 
Controls ± 48 healthy; Mean 
age 31.4±12.7 y; 33M, 15F 
x Cohort 2: Cases - 
24 OSCC patients; Mean age 
64.9±15.2 y; 14M, 10F. 
Controls - 24 healthy; Mean 
age 41.1±13.4 y; 14M, 10F 
x Cohort 3: Cases - 
30 OSCC patients; Mean age 
54.5±8 y; 21M, 9F. Controls 
- 30 healthy; Mean age 
51.5±11.4 y; 20M, 10F 
x Cohort 4: Cases - 
36 OSCC patients; Mean age 
58.8±13.5 y; 30M, 6F. 
Controls - 54 healthy; Mean 
age 59.9±9.1 y; 50M, 4F 
x Cohort 5: Cases ± 
31 OSCC patients; Mean age 
63.3±11.0; 26M, 4F. 
Controls - 70 healthy; Mean 
age 60.7±10.0; 61M, 8F 
x NS x qPCR x IL8 
x SAT 
x IL1B 
x DUSP1 
x OAZ1  
x H3F3A 
x S100P 
x Expression of 
IL-8 and SAT was 
increased in all 5 
cohorts  
x Expression of 
IL1B, DUSP1, OAZ1 
and H3F3A was 
increased in only 3 
cohorts 
x Expression of 
S100P was increased in 
2 cohorts 
x Biomarke
rs showed their 
feasibility in 
discrimination of 
OSCC from healthy 
controls 
Momen-
Heravi et al. 
(2014), USA28 
x Case-control 
x Stomatology 
Center, Texas A&M 
University±Baylor 
College of Dentistry, 
Texas, USA; 2010 to 
2011 
x Cases: 35 patients 
x 9 OSCC patients 
before treatment; Mean age 
60.6±11.8 y; 8M, 1F 
x 9 patients with 
OSCC-R; Mean age 
69.71±16.8 y;  
x 9 patients with 
OLP; Mean age 66.25±13.67 
y 
x Controls: 8 healthy 
individuals; 60.19±9.6 y 
x NS x RT-
qPCR 
x miR-
136 
x miR-
147 
x miR-
1250 
x miR-
148a 
x miR-
632 
x miR-
646 
x miR-
668 
x miR䯉 191, 
miR䯉 136, miR䯉 147, 
miR䯉 1250, miR䯉 632, 
miR䯉 646, miR䯉 668, 
miR䯉 877, miR䯉 503, 
miR䯉 200a and 
miR䯉 323䯉 5p were 
downregulated in 
OSCC 
x miR䯉 24 and 
miR䯉 27b were 
upregulated in OSCC 
x miR-136 was 
underexpressed in 
x miR-27b 
can be a potential 
OSCC salivary 
biomarker 
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x miR-
877 
x miR-
503 
x miR-
220a 
x miR-
323-5p 
x miR-24 
x miR27b 
OSCC vs. HC and 
OSCC vs. OSCC-R 
x miR-27b 
levels were significantly 
higher in OSCC 
patients compared to 
HC, patients with 
OSCC-R, and patients 
OLP 
Zahran et al. 
(2015), Saudi 
Arabia29 
x Case-control 
x Outpatient 
clinic of Oral Medicine 
and Periodontology 
Department, Faculty of 
Oral and Dental 
Medicine, Cairo 
University and National 
Cancer Institute in Cairo, 
Egypt 
x Cases: 
x 40 OPMD patients; 
Mean age 54.2±9.7 y; 22M, 
18F 
x 20 OSCC patients; 
Mean age 58±9.2 y; 8M, 12F 
x Controls:  
x 20 healthy 
individuals; Mean age 
51.1±9.3 y; 9M, 11F 
x 20 RAS patients; 
Mean age 28±7.3 y; 7M, 13 
F 
x Buccal 
mucosa 
x Tongue 
x Floor of 
mouth 
x Retro-
molar  
x Lower 
alveolar 
x qRT-
PCR 
x miR-21 
x miR-
184 
x miR-
145 
x Expression of 
miR-21 and miR-184 
was increased in OSCC 
and OPMD patients 
compared to healthy 
and disease controls 
x Expression of 
miR-145 was reduced 
in OSCC and OPMD 
patients 
x miR-184 
may be a potential 
diagnostic 
biomarkers for oral 
malignant 
transformation 
Hung et al. 
(2016), 
Taiwan30 
x Case-control 
x Department of 
Dentistry, School of 
Dentistry, National 
Yang-Ming University, 
Taipei, Taiwan 
x Cases: 46 patients 
newly diagnosed as OPMD; 
Mean age 53.3±3.7 y; 42M, 
4F. 
x Controls: 24 
healthy individuals; Mean 
age 52.9±3.2 y; 20M, 4F. 
x Buccal 
mucosa 
x Gingiva 
x Lip 
x Palate 
x Tongue 
x qRT-
PCR 
x In situ 
hybridization 
(ISH) 
x miR-21  
x miR-31 
x Expression of 
salivary miR-21 and 
miR-31 was increased 
in OPMD patients 
compared to control 
individuals 
x Patients with 
recurrent OPMD and/or 
malignant 
transformation 
exhibited a further 
augmented expression 
of miR-31 
x Salivary 
miR-21 and miR-31 
are useful OPMD 
screening tools 
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OSCC ± Oral squamous cell carcinoma; NS ± Not stated; M ± Male; F ± Female; HC ± Healthy controls; OSCC-R ± Oral squamous cell carcinoma in remission; OPMD ± Oral potentially 
malignant disorders; TSCC ± Tongue squamous cell carcinoma; qRT-PCR - Quantitative reverse transcription polymerase chain reaction; RT-qPCR - Real-time quantitative polymerase chain 
reaction; qPCR - Quantitative polymerase chain reaction; RT-preamp-qPCR - reverse transcriptasepreamplification-quantitative PCR () 
 
 
Table 1. Characteristics of the included studies  
  
Duz et al. 
(2016), 
Turkey31 
x Case-control 
x Department of 
Otorhinolaryngology, 
Cerrahpasa Medical 
School, Istanbul 
University 
x Cases: 25 TSCC 
patients; Mean age 
54.08±2.4 y; 19M, 6F. 
x Controls: 25 
healthy individuals; age, 
gender matched; similar 
smoking and alcohol habits 
as cases; Mean age 
46.88±3.6 y; 21M, 4F. 
x Tongue x qRT-
PCR 
x Microarr
ay-based miRNA 
x miR-
139-5p 
x Expression of 
miR-139-5p was 
reduced in TSCC saliva 
samples compared to 
control saliva samples 
x In post-
operative saliva samples 
of TSCC patients the 
miR-139-5p expression 
levels returned to 
normal 
x miR-139-
5p may serve as a 
potential biomarker 
for early TSCC 
detection 
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Author et al. (year) Molecules analyzed Sensitivity Specificity AUC 
Li et al. (2004)23 
IL8 
IL1B 
DUSP1 
H3F3A 
OAZ1 
S100P 
SAT 
88% 
63% 
59% 
53% 
100% 
72% 
81% 
81% 
72% 
75% 
81% 
38% 
63% 
56% 
0.85 
0.70 
0.65 
0.68 
0.69 
0.71 
0.70 
Park et al. (2009)24 
miR-200a 
miR-125a 
miR-142-3p 
miR-93 
NS NS 
0.65 
0.62 
0.58 
0.57 
Brinkmann et al. (2011)25 
IL8  
S100P  
SAT1 
OAZ1 
IL1B 
DUSP1 
60% 
54% 
54% 
40% 
23% 
14% 
78% 
88% 
82% 
92% 
94% 
98% 
0.75 
0.71 
0.70 
0.60 
0.42 
0.41 
Liu et al. (2012)26 miR-31 NS 100% 0.82 
Elashoff et al. (2012)27 
IL8 
SAT 
IL1B 
DUSP1 
OAZ1  
H3F3A 
S100P 
68% 
66% 
65% 
60% 
62% 
61% 
60% 
64% 
63% 
60% 
65% 
58% 
56% 
56% 
0.74 to 0.86 across the cohorts 
Momen-Heravi et al. (2014)28 miR-27b 85.71% 100% 0.9643 
Zahran et al. (2015)29 
miR-184 
miR-21 
miR-145 
80% 
65% 
60% 
75% 
65% 
70% 
0.86 
0.73 
0.68 
Hung et al. (2016)30 miR-21 
miR-31 
100 % 
100 % NS 
0.74 
0.76 
Duz et al. (2016)31 miR-139-5p NS NS 0.805 
    
   AUC - Area under ROC curve; NS ± Not stated 
Table 2. Sensitivity, specificity and receiver operator characteristic (ROC) curve analysis of OSCC-associated salivary biomarkers 
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